{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T01:31:18Z","timestamp":1765503078449,"version":"3.48.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endoscopic retrograde cholangiopancreatography (ERCP) is valuable in management of primary sclerosing cholangitis (PSC). Herein, we characterize individuals with PSC who underwent ERCP on-demand at a high-volume quaternary centre, with evaluation of pathology results and short-term postprocedural outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study evaluated patients with PSC who underwent ERCP at St Michael\u2019s Hospital between April 2011 and July 2021. Chart review was conducted to collect clinical, procedural, and pathology data, and reported post-ERCP complications within 90\u2009days. Logistic regression analyses were conducted to evaluate factors associated with post-ERCP complications and placement of a biliary stent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and sixty-seven patients with PSC underwent 464 ERCPs (69% males, median age 45\u2009years). The median duration of PSC diagnosis prior to ERCP was 6.7\u2009years and 42% of procedures were in patients with cirrhosis. Symptoms pre-ERCP included jaundice, abdominal pain, subjective fevers, and pruritus. Stent insertion at procedure was associated with presentations with jaundice or elevated bilirubin, prior stent insertion, and\/or concern for malignancy. Stent insertion was also associated with post-ERCP complications within 90\u2009days. Neoplastic pathology was identified in 20% of cytology samples and 27% of biliary biopsies. There were no significant differences in symptomology at presentation between patients with and without neoplastic pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis patients undergoing ERCP have high symptom burden and rates of neoplastic pathology, with high rates of recurrent obstruction post-ERCP. Stent insertion is associated with a sicker PSC phenotype and higher risk of post-ERCP complications. Future studies are needed to further explore the role of ERCP in management of PSC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwaf018","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T07:35:42Z","timestamp":1750577742000},"page":"228-234","source":"Crossref","is-referenced-by-count":0,"title":["Endoscopic retrograde cholangiopancreatography and primary sclerosing cholangitis: a retrospective study of a high-volume program"],"prefix":"10.1093","volume":"8","author":[{"given":"Kristel K","family":"Leung","sequence":"first","affiliation":[{"name":"The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital , Toronto, Ontario, M5G 2C4,","place":["Canada"]},{"name":"Division of Gastroenterology, Department of Medicine, Queen\u2019s University , Kingston, Ontario, K7L 3N6,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8463-6601","authenticated-orcid":false,"given":"Michael","family":"Youssef","sequence":"additional","affiliation":[{"name":"The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital , Toronto, Ontario, M5G 2C4,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital , Philadelphia, Pennsylvania, 19107,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Streutker","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Ontario, M5S 1A1,","place":["Canada"]},{"name":"Division of Gastroenterology and Hepatology, St. Michael\u2019s Hospital , Toronto, Ontario, M5B 1W8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya","family":"Gulamhusein","sequence":"additional","affiliation":[{"name":"The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital , Toronto, Ontario, M5G 2C4,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Hansen","sequence":"additional","affiliation":[{"name":"Erasmus Medical Centre , Rotterdam, 3015 GD,","place":["Netherlands"]},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto , Toronto, Ontario, M5S 1A1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Calo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, St. Michael\u2019s Hospital , Toronto, Ontario, M5B 1W8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"May","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, St. Michael\u2019s Hospital , Toronto, Ontario, M5B 1W8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Mosko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, St. Michael\u2019s Hospital , Toronto, Ontario, M5B 1W8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital , Toronto, Ontario, M5G 2C4,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025121120262992500_gwaf018-B1","doi-asserted-by":"publisher","first-page":"e0590","DOI":"10.1097\/HC9.0000000000000590","article-title":"Management of primary sclerosing cholangitis: current state-of-the-art","volume":"8","author":"Can\u00e7ado","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025121120262992500_gwaf018-B2","doi-asserted-by":"publisher","first-page":"101272","DOI":"10.1016\/j.jhepr.2024.101272","article-title":"Primary sclerosing cholangitis\u2013inflammatory bowel disease: epidemiology, mortality, and impact of diagnostic sequence","volume":"7","author":"Leung","year":"2025","journal-title":"JHEP Rep"},{"key":"2025121120262992500_gwaf018-B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5946\/CE.2020.019-IDEN","article-title":"Role of endoscopy in primary sclerosing cholangitis","volume":"54","author":"Bhat","year":"2021","journal-title":"Clin Endosc"},{"key":"2025121120262992500_gwaf018-B4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1055\/s-0043-107029","article-title":"Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, F\u00e4rkkil\u00e4 M, Fickert P, Hirschfield GM, Laghi A, Marzioni M. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"2025121120262992500_gwaf018-B5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1067\/mge.2002.129086","article-title":"Risk factors for complications after performance of ERCP","volume":"56","author":"Vandervoort","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"2025121120262992500_gwaf018-B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/liv.12640","article-title":"Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography","volume":"35","author":"von Seth","year":"2015","journal-title":"Liver Int"},{"key":"2025121120262992500_gwaf018-B7","doi-asserted-by":"publisher","first-page":"2372257","DOI":"10.1155\/2022\/2372257","article-title":"ERCP-related adverse events in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"2022","author":"Natt","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2025121120262992500_gwaf018-B8","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"Rupp","year":"2019","journal-title":"Gut"},{"key":"2025121120262992500_gwaf018-B9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/liv.15286","article-title":"Impact on follow-up strategies in patients with primary sclerosing cholangitis","volume":"43","author":"Bergquist","year":"2023","journal-title":"Liver Int"},{"key":"2025121120262992500_gwaf018-B10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17474124.2018.1483719","article-title":"Endoscopic management of primary sclerosing cholangitis","volume":"12","author":"Tabibian","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025121120262992500_gwaf018-B11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"2025121120262992500_gwaf018-B12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025121120262992500_gwaf018-B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.01","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol"},{"key":"2025121120262992500_gwaf018-B14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-Centre experience","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121120262992500_gwaf018-B15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment","volume":"71","author":"Gotthardt","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"2025121120262992500_gwaf018-B16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/MCG.0b013e3181646713","article-title":"A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis","volume":"42","author":"Gluck","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"2025121120262992500_gwaf018-B17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"2025121120262992500_gwaf018-B18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jmoldx.2015.08.002","article-title":"Next-generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy","volume":"18","author":"Dudley","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025121120262992500_gwaf018-B19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jcag\/gwy020","article-title":"A cholangioscopy-based novel classification system for the phenotypic stratification of dominant bile duct strictures in primary sclerosing cholangitis-the Edmonton classification","volume":"1","author":"Sandha","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025121120262992500_gwaf018-B20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025121120262992500_gwaf018-B21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262992500_gwaf018-B22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.gie.2014.06.030","article-title":"ERCP-related adverse events in patients with primary sclerosing cholangitis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"2025121120262992500_gwaf018-B23","doi-asserted-by":"publisher","first-page":"E710","DOI":"10.1055\/s-0043-102398","article-title":"New approach to decrease post-ERCP adverse events in patients with primary sclerosing cholangitis","volume":"5","author":"Navaneethan","year":"2017","journal-title":"Endosc Int Open"},{"key":"2025121120262992500_gwaf018-B24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/6\/228\/63969429\/gwaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/6\/228\/63969429\/gwaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T01:26:34Z","timestamp":1765502794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/8\/6\/228\/8223432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwaf018","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"type":"print","value":"2515-2084"},{"type":"electronic","value":"2515-2092"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,6]]}}}